* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Mito-PROTAC technology, also referred to as mitochondrial-targeted PROTAC (MtPTAC), is a mitochondria-directed targeted protein degradation strategy that applies E3 ubiquitin ligase-mediated degradation logic to mitochondrial or mitochondria-associated proteins. It is designed to induce selective ubiquitination and proteasome-dependent degradation of a protein of interest (POI), especially when conventional inhibition cannot fully reveal mitochondrial target biology. Unlike conventional Proteolysis Targeting Chimera (PROTAC) technology, Mito-PROTAC development must address mitochondrial localization, membrane permeability, submitochondrial accessibility, and target topology. The POI may be located on the outer mitochondrial membrane (OMM), inner mitochondrial membrane, intermembrane space, or matrix, which directly affects E3 ligase selection, linker design, cellular distribution, and degradation assay strategy.
A typical Mito-PROTAC molecule contains a POI-binding ligand, an E3 ubiquitin ligase ligand, an optimized linker, and, when needed, a mitochondrial localization feature. This technology is suitable for studying ligandable mitochondrial enzymes, membrane-associated mitochondrial proteins, mitochondrial signaling targets, apoptosis-related proteins, and mitochondrial protein quality-control pathways.
BOC Sciences' Comprehensive Mito-PROTAC Technology Development Services
Target Discovery and Validation Services
BOC Sciences helps clients identify mitochondrial or mitochondria-associated targets with biological relevance, ligandability, and degradation feasibility.
Mitochondrial protein target screening: Degradable targets are selected based on mitochondrial proteomics data, pathway relevance, and disease-related biology in oncology, metabolism, and neurodegeneration research.
Target druggability assessment: Submitochondrial localization, surface accessibility, ligandable regions, and E3 ligase accessibility are evaluated to determine technical feasibility.
Target functional validation: Knockout or knockdown-based studies help confirm whether target depletion produces meaningful biological effects.
Project initiation support:Target protein services provide a practical foundation for early mitochondrial target validation.
Mito-PROTAC Molecular Design Services
Mito-PROTAC design requires coordinated optimization of the POI ligand, E3 ubiquitin ligase ligand, linker, and mitochondrial targeting feature.
Mitochondria-targeting moiety design: TPP+, mitochondria-penetrating peptides, and targeting small molecules can be designed or screened to improve mitochondrial localization.
Target protein and E3 ligand design: Ligands are selected or optimized for mitochondrial POIs and E3 systems such as MARCH5, Parkin, VHL, or CRBN.
Linker architecture optimization: Linker length, rigidity, polarity, and cleavability are adjusted to balance ternary complex formation, mitochondrial exposure, and degradation efficiency.
Computational design support:PROTAC design services and molecular modeling help predict productive POI–Mito-PROTAC–E3 engagement.
Chemical Synthesis and Process Development Services
BOC Sciences supports custom synthesis and chemistry optimization for Mito-PROTAC candidates, analog libraries, and modular degrader intermediates.
Custom Mito-PROTAC synthesis: Milligram- to gram-scale synthesis is available for research-stage screening, validation, and structure optimization.
MTS-linker-warhead modular synthesis: Mitochondrial targeting groups, linkers, POI ligands, and E3 ligase ligands are assembled to enable rapid analog generation.
Chirality and isomer control: Defined stereochemical configurations can be prepared when activity comparison requires chiral or isomer-specific molecules.
Route optimization:Custom PROTAC synthesis services support complex bifunctional degrader construction and synthetic route refinement.
Efficient mitochondrial enrichment is essential for Mito-PROTAC activity, especially when the target is located within a specific submitochondrial compartment.
Mitochondrial membrane penetration optimization: Charge density, lipophilicity, and targeting group design are tuned to improve mitochondrial membrane penetration.
Submitochondrial localization design: Mito-PROTAC variants can be designed for matrix-, inner membrane-, or outer membrane-associated target engagement.
Off-target distribution assessment: Distribution in non-mitochondrial organelles is evaluated to refine targeting specificity.
Cellular exposure troubleshooting:PROTAC cellular permeability assay helps determine whether weak activity is related to poor cellular entry or mitochondrial exposure.
In Vitro Activity and Mechanism Validation Services
In vitro and cell-based assays are used to evaluate degradation potency, ternary complex formation, ubiquitination, pathway dependence, and mitochondrial functional response.
Mitochondrial protein degradation detection: Target degradation is quantified by Western blot, immunoassay, or mass spectrometry, with DC50 and Dmax analysis.
Ternary complex validation: Co-IP, affinity pull-down assays, or orthogonal protein interaction analysis can be used to evaluate POI–Mito-PROTAC–E3 complex formation.
Ubiquitination and pathway analysis: Target ubiquitination, ubiquitin chain type, proteasome dependence, and autophagy-related contribution are assessed where appropriate.
Functional response evaluation:Degradation ability assay can be combined with ΔΨm, reactive oxygen species (ROS), adenosine triphosphate (ATP), and respiratory chain readouts.
In Vivo Efficacy and Pharmacokinetics Services
For advanced research programs, BOC Sciences supports in vivo efficacy and pharmacokinetics (PK) studies to evaluate exposure, distribution, target degradation, and biological response.
Research model selection: Mitochondrial dysfunction-related models, including MPTP-induced Parkinson's disease models and tumor xenograft models, can be selected according to project goals.
In vivo targeting and distribution study: Fluorescent or radiolabeled tracing strategies are used to evaluate tissue distribution and mitochondrial targeting efficiency.
Pharmacodynamic evaluation: Target degradation and biological response markers such as tumor growth inhibition, neuroprotective effects, or metabolic indicator changes are assessed.
PK and mitochondrial response assessment: Plasma and tissue exposure, half-life, clearance, mitochondrial DNA copy number, respiratory chain function, and oxidative stress markers can be monitored.
Have You Encountered Following Challenges in Mito-PROTAC Development?
Uncertainty about whether your mitochondrial target is accessible to degrader-induced proximity
Difficulty choosing between protease-based, ubiquitination-based, or mitophagy-related degradation mechanisms
Limited availability of suitable ligands for mitochondrial matrix or inner membrane proteins
Weak degradation despite measurable POI binding or mitochondrial accumulation
Our Solutions for Mito-PROTAC Development Challenges
Mito-PROTAC projects are technically demanding because target biology, mitochondrial topology, degrader permeability, protease recruitment, linker geometry, and assay interpretation must be aligned. BOC Sciences provides integrated solutions that connect molecular design with mechanism-focused validation, enabling clients to make data-driven decisions at each stage of mitochondria-directed degrader development.
Solution for Target Topology and Degradation Route Selection
A mitochondrial protein may be located on the OMM, embedded in the inner mitochondrial membrane, exposed to the intermembrane space, or localized in the matrix. Each location imposes different design rules. We map the target's topology, ligand accessibility, mitochondrial import status, and degradation machinery exposure, then recommend a practical route such as ClpP-recruiting MtPTAC-like design, OMM-directed ubiquitination evaluation, or comparative mitophagy-related exploration.
Solution for Mitochondrial Entry and Cellular Exposure
Many bifunctional degraders fail because they are too large, too polar, or poorly distributed across mitochondrial membranes. We address this by balancing molecular weight, polarity, linker composition, ionizable groups, and mitochondrial targeting features. When needed, we integrate PROTAC cellular permeability assay support to determine whether weak degradation is caused by insufficient cellular entry, poor mitochondrial accumulation, or nonproductive molecular design.
Solution for Linker Geometry and Ternary Proximity
Mito-PROTAC activity requires the POI and mitochondrial protease or degradation component to be positioned in a productive orientation. If a linker is too short, too flexible, too rigid, or attached at the wrong exit vector, binary binding may occur without degradation. We compare structured linker matrices and use degradation data to identify designs that improve target–degrader–protease proximity while preserving mitochondrial compatibility.
Solution for Mechanistic Confirmation and Data Interpretation
Protein reduction in mitochondrial assays can result from genuine target degradation, altered mitochondrial biogenesis, general cell stress, or reduced protein synthesis. Our validation plans include dose-response and time-course profiling, competition experiments, protease-dependence analysis, mitochondrial fractionation, pathway rescue studies, and PROTAC selectivity evaluation to help clients interpret whether observed protein loss reflects the intended Mito-PROTAC mechanism.
Choose BOC Sciences to Build More Reliable Mito-PROTAC Degradation Programs!
From mitochondrial target feasibility and degrader architecture design to custom synthesis, cellular degradation profiling, and mechanism-driven optimization, BOC Sciences provides tailored support for mitochondria-directed protein degradation projects. Our interdisciplinary expertise helps clients reduce design uncertainty, generate decision-ready data, and identify stronger Mito-PROTAC candidates for continued research.
Our Mito-PROTAC Solutions Support Diverse R&D Organizations
Pharmaceutical Discovery Teams
Pharmaceutical research teams may use Mito-PROTAC technology to explore mitochondrial proteins that are difficult to address using occupancy-based inhibitors or conventional PROTAC modalities. We support target assessment, design strategy, synthesis, degradation validation, and optimization cycles for mitochondrial disease biology, oncology research, and metabolic pathway studies.
Biotechnology Companies
Biotechnology companies often need rapid proof-of-concept data to decide whether mitochondrial targeted protein degradation can support a new discovery program. BOC Sciences helps accelerate early decision-making through focused Mito-PROTAC design, analog generation, mitochondrial localization studies, and cell-based degradation screening.
Academic and Translational Research Groups
Research groups can use Mito-PROTAC molecules as chemical biology tools to investigate mitochondrial protein function, organelle proteostasis, metabolic remodeling, mitochondrial transcription, oxidative phosphorylation, apoptosis signaling, and mitophagy-related processes. We provide flexible service modules that support exploratory and mechanism-focused research.
CROs and Technical Service Platforms
CROs and technical platforms may require specialized mitochondria-directed degrader expertise to complement internal chemistry, modeling, or biology capabilities. We offer modular cooperation models covering molecular design, linker optimization, custom synthesis, assay development, and degradation data interpretation for collaborative project execution.
End-to-End Mito-PROTAC Technology Development Workflow
01
Inquiry and Project Requirement Collection
Understand the client's mitochondrial target, available ligands, target localization, desired degradation readouts, preferred cell models, project stage, and technical objectives.
02
Target Feasibility and Mechanism Strategy Assessment
Evaluate mitochondrial topology, ligandability, protease accessibility, degradation route feasibility, assay availability, and potential technical risks to define a realistic development strategy.
03
Proposal Design, Scope Definition, and Quotation
Prepare a tailored research plan covering molecular design scope, analog number, synthesis plan, assay package, data output, and decision points for optimization.
04
Technical Data Transfer and Project Initiation
Receive target information, ligand structures, assay protocols, reference compounds, mitochondrial localization data, and project background materials required for efficient execution.
05
Mito-PROTAC Design and Candidate Prioritization
Design candidate molecules by combining POI ligands, mitochondrial protease recruiters or degradation modules, optimized linkers, and mitochondrial compatibility considerations.
06
Synthesis of Focused Mito-PROTAC Analog Series
Synthesize prioritized candidates and analog sets for comparative evaluation of linker length, recruiter type, mitochondrial localization, and target degradation performance.
07
In Vitro and Cell-Based Degradation Validation
Evaluate target protein degradation, dose response, time dependence, mitochondrial localization, protease dependence, cellular response, and pathway-specific readouts.
08
Optimization, Reporting, and Next-Step Recommendation
Refine the POI ligand, protease recruiter, linker, and physicochemical properties based on degradation potency, Dmax, mitochondrial response, and selectivity data.
Advantages
Advantages of Mito-PROTAC Technology
Expands TPD into Mitochondrial Compartments
Mito-PROTAC technology provides a route to investigate mitochondrial proteins that are poorly addressed by conventional UPS- or lysosome-dependent degradation strategies, especially targets located inside mitochondrial compartments.
Supports Protein Removal Instead of Occupancy Only
By reducing target protein abundance, Mito-PROTAC molecules can help researchers evaluate whether mitochondrial pathway modulation is better achieved through degradation rather than simple inhibition.
Enables Study of Mitochondrial Proteostasis
Mito-PROTAC design can support research into ClpP-mediated degradation, LONP1-associated proteostasis, mitochondrial transcription, oxidative phosphorylation, mitochondrial dynamics, and organelle quality control.
Creates New Options for Difficult Targets
Mitochondrial enzymes, scaffold proteins, transcription-related proteins, and membrane-associated proteins may present challenging binding or accessibility profiles. Mito-PROTAC technology offers an alternative design logic for these difficult targets.
Applications
Applications Supported by Our Mito-PROTAC Technology Platform
Oncology Research
Degradation strategy development for mitochondria-associated survival proteins, apoptosis regulators, and metabolic enzymes involved in tumor cell adaptation.
Mito-PROTAC design for targets such as BCL-2 family proteins, mitochondrial metabolic enzymes, and mitochondria-linked signaling proteins.
Evaluation of target degradation effects on tumor cell proliferation, apoptosis, mitochondrial membrane potential ΔΨm, reactive oxygen species (ROS), and adenosine triphosphate (ATP) production.
Exploration of Mito-PROTAC strategies for mitochondrial dysfunction-associated targets in Parkinson's disease, Alzheimer's disease, and related neurodegeneration models.
Target degradation studies for proteins involved in oxidative stress, mitochondrial quality control, impaired energy metabolism, and neuronal survival pathways.
Assessment of mitochondrial functional readouts, including ΔΨm, ROS accumulation, respiratory chain activity, and ATP generation after target depletion.
Support for mechanism-focused studies involving Parkin-related mitochondrial quality control and mitochondria-associated degradation pathways.
Metabolic Disease Research
Development of Mito-PROTAC candidates for mitochondrial enzymes and regulatory proteins involved in fatty acid oxidation, glucose metabolism, and energy homeostasis.
Evaluation of target degradation effects on mitochondrial respiration, substrate utilization, ATP output, and metabolic stress response.
Application in cellular models related to insulin resistance, hepatic metabolic dysfunction, obesity-associated mitochondrial stress, and impaired oxidative metabolism.
Combination with degradation ability assay to compare DC50, Dmax, and degradation kinetics across metabolic target candidates.
Cardiovascular Disease Research
Mito-PROTAC technology can be applied to study mitochondrial proteins associated with cardiomyocyte energy metabolism, oxidative stress, and stress-induced mitochondrial injury.
Degrader design support for targets involved in mitochondrial calcium handling, respiratory chain regulation, apoptosis signaling, and ischemia-reperfusion-related stress response.
Functional evaluation may include mitochondrial membrane potential, ROS levels, ATP production, cell viability, and pathway-specific response markers.
Candidate optimization can be guided by mitochondrial localization, target degradation potency, and cell-context-dependent functional outcomes.
Case Study
Client Success Stories: Mito-PROTAC Technology Development
Project Background
A biotechnology research team wanted to determine whether a mitochondrial matrix protein involved in mitochondrial transcription could be depleted using a protease-recruiting degrader strategy. The client had a POI-binding small molecule with measurable activity in cellular assays, but the original ligand had no defined degrader exit vector and the team was unsure whether mitochondrial protease recruitment could produce selective protein loss without broad mitochondrial stress.
Our Support
BOC Sciences first reviewed the target structure, mitochondrial localization, and known ligand binding mode. We identified two feasible derivatization positions on the POI ligand and designed a 22-compound Mito-PROTAC matrix using two ClpP-recruiting motifs and PEG, alkyl, and semi-rigid linkers ranging from 5 to 15 atoms. After synthesis, candidates were evaluated in a mitochondrial target-expressing cellular model using 6 h, 16 h, and 24 h treatment windows. Early analogs with long PEG linkers showed mitochondrial accumulation but weak degradation, suggesting poor ternary proximity. A second prioritized set with mid-length semi-rigid linkers improved target reduction and showed clearer time-dependent degradation. The best molecule achieved approximately 65% target protein reduction at 24 h under optimized assay conditions, while mitochondrial fractionation and competition studies supported a target-directed degradation mechanism.
Client Testimonial
BOC Sciences helped us convert a difficult mitochondrial target concept into a structured degrader workflow. Their ability to connect target topology, ClpP recruitment, linker design, and cellular readout interpretation gave us a much clearer optimization path.
Project Background
A drug discovery group was exploring degradation of a mitochondrial inner membrane enzyme involved in nucleotide metabolism. The client had an inhibitor scaffold with a defined binding pocket but saw inconsistent protein reduction from early degrader attempts. They needed help redesigning the Mito-PROTAC architecture, improving mitochondrial compatibility, and distinguishing enzyme inhibition from true degradation.
Our Support
We analyzed the inhibitor binding orientation and found that the original linker attachment site likely restricted productive exposure toward the mitochondrial matrix-facing protein surface. We proposed a new attachment strategy and designed 18 candidates combining a modified POI ligand, three linker families, and two mitochondrial protease recruiter designs. Binding analysis confirmed that several analogs retained POI engagement, but the first degradation screen showed that highly flexible linkers generated weak and variable protein loss. We then introduced a heterocyclic linker series with improved polarity distribution and reduced conformational freedom. The optimized candidate showed reproducible target degradation across two cell models, with Dmax above 50% in the best condition and a stronger separation between degradation response and general mitochondrial membrane potential ΔΨm changes. The final data package gave the client a defined lead-like molecular template for further analog expansion.
Client Testimonial
The BOC Sciences team did more than synthesize analogs. They helped us understand why our early Mito-PROTAC designs failed and built a practical design–synthesis–assay cycle that produced interpretable degradation data.
Why Us
Why Choose BOC Sciences for Your Mito-PROTAC Project?
Integrated Mitochondrial Degrader Development
We provide coordinated support across target assessment, mitochondrial degrader design, custom synthesis, cellular evaluation, mechanism validation, and optimization.
Deep Understanding of Mitochondrial Target Biology
Our team considers submitochondrial localization, protein topology, mitochondrial import, protease accessibility, and cellular context when designing Mito-PROTAC strategies.
Flexible Modular Service Models
Clients can access single-service support such as linker design, synthesis, or degradation assays, or request end-to-end Mito-PROTAC technology development.
Mechanism-Focused Validation
Our validation workflows help determine whether observed protein reduction is consistent with mitochondrial degrader-induced proximity and target-specific degradation.
Data-Driven Optimization
We connect chemistry, mitochondrial localization, degradation potency, selectivity, and pathway response data to guide rational design iteration.
Clear Reporting and Decision Support
We provide organized experimental data, practical interpretation, and clear recommendations for the next stage of Mito-PROTAC design, screening, or optimization.
Mito-PROTAC is a targeted protein degradation strategy that combines mitochondrial targeting with PROTAC (Proteolysis Targeting Chimera) technology to induce selective ubiquitination and proteasomal degradation of mitochondria-associated target proteins. Compared with conventional PROTACs, Mito-PROTAC design must consider not only the target protein ligand, E3 ligase ligand, and linker architecture, but also subcellular distribution, mitochondrial localization efficiency, membrane accessibility, and mitochondrial functional readouts. BOC Sciences provides research services covering Mito-PROTAC molecular design, synthesis, cellular degradation evaluation, mitochondrial localization validation, and mechanism confirmation, helping drug discovery teams systematically explore the degradation feasibility of mitochondrial targets.
How does Mito-PROTAC reach mitochondria?
Mito-PROTACs reach mitochondria mainly through rational mitochondrial-targeting design rather than passive diffusion alone. Common strategies include introducing mitochondria-targeting motifs such as lipophilic cationic groups, using ligands that recognize mitochondria-associated proteins, or optimizing the molecular structure to favor mitochondrial enrichment. In many designs, the compound does not necessarily need to enter the mitochondrial matrix; it may act on mitochondria-associated proteins exposed on the outer mitochondrial membrane or localized near mitochondrial compartments. Therefore, successful Mito-PROTAC development requires careful balancing of mitochondrial targeting, cellular permeability, linker architecture, E3 ligase recruitment, and proteasome-dependent degradation. BOC Sciences can support mitochondrial localization validation through subcellular fractionation, fluorescence imaging, co-localization analysis, and target degradation assays.
Which mitochondrial targets suit Mito-PROTAC?
Mito-PROTAC is more suitable for targets with clear mitochondrial localization, recognizable small-molecule ligands, and measurable changes in cellular phenotype or protein abundance after degradation. These may include proteins associated with the outer mitochondrial membrane, inner mitochondrial membrane, mitochondrial quality control, energy metabolism, oxidative stress, or cell death pathways. At the early project stage, researchers typically need to evaluate target accessibility, subcellular localization stability, ligand-binding window, E3 ligase selection feasibility, and whether target degradation can generate mechanism-relevant readouts.
How can Mito-PROTAC activity be validated?
The activity of a Mito-PROTAC should not be judged only by a decrease in target protein level. Instead, it should be confirmed using multiple readouts, including degradation efficiency, DC50, Dmax, time dependence, proteasome dependence, E3 ligase dependence, mitochondrial localization changes, and functional mitochondrial indicators. BOC Sciences commonly recommends combining Western blot, immunofluorescence, subcellular fractionation, competition experiments, proteasome inhibition experiments, and mitochondrial function analysis to distinguish true degradation from transcriptional downregulation, mitochondrial stress, or nonspecific cytotoxicity.
What are common Mito-PROTAC development challenges?
Common challenges in Mito-PROTAC development include limited availability of mitochondrial target ligands, complex target localization, mismatched E3 ligase expression in relevant cell models, insufficient access of molecules to the mitochondrial environment, difficulty distinguishing degradation signals from mitochondrial damage, and inconsistent results across different cellular systems. Therefore, project design should integrate target feasibility assessment, ligand modification, E3 ligase selection, linker matrix design, cell model selection, and validation strategy from the beginning. BOC Sciences provides modular support from molecular design and synthesis to cellular degradation evaluation and mechanism confirmation.
Quick Inquiry
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
We invite you to contact us at or through our contact form above for more information about our services and products.
Expands TPD into Mitochondrial Compartments
